Tirier, Stephan M.
Mallm, Jan-Philipp
Steiger, Simon http://orcid.org/0000-0002-4845-5042
Poos, Alexandra M.
Awwad, Mohamed H. S. http://orcid.org/0000-0003-4514-7199
Giesen, Nicola http://orcid.org/0000-0002-9615-2564
Casiraghi, Nicola
Susak, Hana http://orcid.org/0000-0002-7965-7675
Bauer, Katharina
Baumann, Anja
John, Lukas http://orcid.org/0000-0001-8178-6890
Seckinger, Anja
Hose, Dirk
Müller-Tidow, Carsten http://orcid.org/0000-0002-7166-5232
Goldschmidt, Hartmut http://orcid.org/0000-0003-0961-0035
Stegle, Oliver
Hundemer, Michael http://orcid.org/0000-0002-5596-2405
Weinhold, Niels
Raab, Marc S. http://orcid.org/0000-0003-4181-6922
Rippe, Karsten http://orcid.org/0000-0001-9951-9395
Funding for this research was provided by:
NCT Heidelberg Molecular Precision Oncology Program, grant HIPO K43R
Dietmar Hopp Stiftung
Article History
Received: 22 January 2021
Accepted: 28 October 2021
First Online: 29 November 2021
Competing interests
: H.G. – Grants/provisions: Amgen, BMS, Celgene, Chugai, Janssen, Johns Hopkins University, Sanofi; Research support: Amgen, BMS, Celgene, Chugai, Janssen, Incyte, Molecular Partners, Merck Sharp and Dohme (MSD), Sanofi, Mundipharma GmbH, Takeda, Novartis; Advisory Boards: Adaptive Biotechnology, Amgen, BMS, Celgene, Janssen, Sanofi, Takeda; Honoraria: Amgen, BMS, Celgene, Chugai, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi. C.M.T. – Grants/provisions: Pfizer, Daiichi Sankyo, BiolineRx; Research support: Abbvie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisai, Fresenius, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, MSD, Novartis, Pharmamar, Pfizer, Roche, Shire, Takeda, Affimed; Advisory Boards: Pfizer, Janssen. The other authors declare no competing interests.